Cargando…
Cabozantinib as first-line treatment in advanced renal cell carcinoma: a profile of its use
Oral cabozantinib tablets (Cabometyx(®)) are an important option for the treatment of advanced renal cell carcinoma (RCC). Cabozantinib is an anti-angiogenic agent and potently inhibits multiple tyrosine kinases, including those implicated in the development of RCC. The previously approved indicatio...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323107/ https://www.ncbi.nlm.nih.gov/pubmed/30679901 http://dx.doi.org/10.1007/s40267-018-0547-6 |
_version_ | 1783385693518561280 |
---|---|
author | Lyseng-Williamson, Katherine A. |
author_facet | Lyseng-Williamson, Katherine A. |
author_sort | Lyseng-Williamson, Katherine A. |
collection | PubMed |
description | Oral cabozantinib tablets (Cabometyx(®)) are an important option for the treatment of advanced renal cell carcinoma (RCC). Cabozantinib is an anti-angiogenic agent and potently inhibits multiple tyrosine kinases, including those implicated in the development of RCC. The previously approved indication of cabozantinib tablets (i.e. treatment of advanced RCC following prior VEGF-targeted therapy) has been extended to include the first-line treatment of advanced RCC in treatment-naïve adults with intermediate or poor risk (EU) and all patients with advanced RCC (USA). These label extensions are based on the results of a randomized, open-label phase 2 trial, in which adults with metastatic RCC of poor or intermediate risk received targeted first-line treatment with cabozantinib or standard-of-care sunitinib. Relative to sunitinib, cabozantinib significantly prolonged median progression-free survival (primary endpoint; investigator and independent assessments), and increased the objective response rate (investigator assessment). The tolerability profile of cabozantinib is comparable to those of other tyrosine kinase inhibitors, with adverse events being manageable with medical intervention, dosage reductions, treatment interruption and/or permanent discontinuation. |
format | Online Article Text |
id | pubmed-6323107 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-63231072019-01-22 Cabozantinib as first-line treatment in advanced renal cell carcinoma: a profile of its use Lyseng-Williamson, Katherine A. Drugs Ther Perspect Adis Drug Q&A Oral cabozantinib tablets (Cabometyx(®)) are an important option for the treatment of advanced renal cell carcinoma (RCC). Cabozantinib is an anti-angiogenic agent and potently inhibits multiple tyrosine kinases, including those implicated in the development of RCC. The previously approved indication of cabozantinib tablets (i.e. treatment of advanced RCC following prior VEGF-targeted therapy) has been extended to include the first-line treatment of advanced RCC in treatment-naïve adults with intermediate or poor risk (EU) and all patients with advanced RCC (USA). These label extensions are based on the results of a randomized, open-label phase 2 trial, in which adults with metastatic RCC of poor or intermediate risk received targeted first-line treatment with cabozantinib or standard-of-care sunitinib. Relative to sunitinib, cabozantinib significantly prolonged median progression-free survival (primary endpoint; investigator and independent assessments), and increased the objective response rate (investigator assessment). The tolerability profile of cabozantinib is comparable to those of other tyrosine kinase inhibitors, with adverse events being manageable with medical intervention, dosage reductions, treatment interruption and/or permanent discontinuation. Springer International Publishing 2018-08-07 2018 /pmc/articles/PMC6323107/ /pubmed/30679901 http://dx.doi.org/10.1007/s40267-018-0547-6 Text en © Springer Nature Switzerland AG 2018, corrected publication 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made. |
spellingShingle | Adis Drug Q&A Lyseng-Williamson, Katherine A. Cabozantinib as first-line treatment in advanced renal cell carcinoma: a profile of its use |
title | Cabozantinib as first-line treatment in advanced renal cell carcinoma: a profile of its use |
title_full | Cabozantinib as first-line treatment in advanced renal cell carcinoma: a profile of its use |
title_fullStr | Cabozantinib as first-line treatment in advanced renal cell carcinoma: a profile of its use |
title_full_unstemmed | Cabozantinib as first-line treatment in advanced renal cell carcinoma: a profile of its use |
title_short | Cabozantinib as first-line treatment in advanced renal cell carcinoma: a profile of its use |
title_sort | cabozantinib as first-line treatment in advanced renal cell carcinoma: a profile of its use |
topic | Adis Drug Q&A |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323107/ https://www.ncbi.nlm.nih.gov/pubmed/30679901 http://dx.doi.org/10.1007/s40267-018-0547-6 |
work_keys_str_mv | AT lysengwilliamsonkatherinea cabozantinibasfirstlinetreatmentinadvancedrenalcellcarcinomaaprofileofitsuse |